Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Capital Expenditures (2021 - 2025)

Historic Capital Expenditures for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $247000.0.

  • Prime Medicine's Capital Expenditures fell 8065.78% to $247000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 1785.37%. This contributed to the annual value of $7.3 million for FY2024, which is 1639.16% down from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Capital Expenditures is $247000.0, which was down 8065.78% from $1.6 million recorded in Q2 2025.
  • Prime Medicine's 5-year Capital Expenditures high stood at $4.8 million for Q4 2022, and its period low was $247000.0 during Q3 2025.
  • For the 5-year period, Prime Medicine's Capital Expenditures averaged around $2.3 million, with its median value being $1.9 million (2023).
  • As far as peak fluctuations go, Prime Medicine's Capital Expenditures skyrocketed by 116020.94% in 2022, and later crashed by 8065.78% in 2025.
  • Over the past 5 years, Prime Medicine's Capital Expenditures (Quarter) stood at $382000.0 in 2021, then skyrocketed by 1160.21% to $4.8 million in 2022, then plummeted by 61.78% to $1.8 million in 2023, then dropped by 2.66% to $1.8 million in 2024, then plummeted by 86.21% to $247000.0 in 2025.
  • Its Capital Expenditures was $247000.0 in Q3 2025, compared to $1.6 million in Q2 2025 and $2.4 million in Q1 2025.